Role of Dopamine Receptors in Primary Focal Dystonias
Information source: Washington University School of Medicine
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy; Focal Dystonias
Phase: N/A
Status: Not yet recruiting
Sponsored by: Washington University School of Medicine Official(s) and/or principal investigator(s):
Morvarid Karimi, MD, Principal Investigator, Affiliation: Washington University School of Medicine
Overall contact:
Pratt Stacey, Phone: 314-747-5916, Email: pratts@npg.wustl.edu
Summary
Dystonia is a disabling movement disorder characterized by repetitive patterned or sustained
muscle contractions causing twisting or abnormal postures that may afflict 250,000 people in
the U. S. While the pathophysiology of dystonia remains uncertain the treatment is rather
rudimentary. A better understanding of neural mechanisms of dystonias is not only an
invaluable prerequisite for developing better treatment options but also a step toward
better understanding of the complex network of basal ganglia. In this study I will
investigate if there is any difference between the dopamine receptors and dopamine in people
with dystonia and healthy subjects.
Clinical Details
Official title: Role of Dopamine Receptors in Primary Focal Dystonias
Study design: Observational Model: Case Control, Time Perspective: Prospective
Eligibility
Minimum age: 21 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age >20
- Male or Female
- Any race or ethnicity
- Primary focal dystonia (arm or cranial)
- Ability to give informed consent
Exclusion criteria:
- Family history of dystonia
- Pregnancy (confirmed with negative urine pregnancy test in women of child bearing
potential), breastfeeding
- Exposure to radiation therapy
- Any MRI contraindications such as foreign metallic implants, pacemaker, and aneurysm
clip etc.
- History of cardiac disease, uncontrolled hypertension, abnormal EKG during screening
phase
- History of exposure to any drugs affecting dopaminergic systems within the last 6
months (e. g. dopamine receptor blocking agents, cocaine, amphetamine, tetrabenazine,
reserpine, L-dopa, dopamine agonists, as they might affect the dopamine receptor
binding or endogenous dopamine).
- Active depression (Beck Depression Inventory_II >14)
- Cognitive impairment (Mini-Mental State Score <27)
- CNS active medications such as gabapentin or narcotics, muscle relaxants which might
be given for pain in the 3 days prior to study
- History of stroke, seizure, cerebral palsy, generalized dystonia, parkinsonism,
inability to hold head still during the scanning time.
Locations and Contacts
Pratt Stacey, Phone: 314-747-5916, Email: pratts@npg.wustl.edu
Washington University, St. Louis, Missouri 63141, United States; Not yet recruiting
Stacey Pratt, Phone: 314-747-5916, Email: pratts@npg.wustl.edu
Morvarid Karimi, MD, Principal Investigator
Additional Information
Starting date: September 2011
Last updated: August 2, 2011
|
